PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. 2025-03-21			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 12.39M 10.93M 10.35M 9.38M 17.59M 1.19B 17.76M 124M 47.83M 607M 46.52M 45.51M 1.95B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 17.57M 15.51M 14.67M 13.31M 24.95M 1.69B 25.19M 176M 67.84M 861M 65.99M 64.55M 2.77B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
24-08-21	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
24-06-24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
24-06-20	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
24-01-15	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
23-12-20	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-14	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
23-05-31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
23-05-31	PCL to Raise 36 Billion Won via Share Issuance	MT
23-03-22	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-12-28	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	87,700
5 years	5,900	340,000
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news: PCL, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	2024-03-27
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	2024-03-27

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	74	-
Mu-Yong So BRD	Director/Board Member	53	2024-03-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-90.00%	12.35M
IOVANCE BIOTHERAPEUTICS, INC.	+31.48%	+35.81%	+547.98%	+217.58%	4.98B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+0.91%	+2.53%	+113.74%	+427.89%	4.55B
VERACYTE, INC.	+1.88%	+6.27%	+37.10%	+106.36%	3.64B
CAREDX, INC.	-0.90%	+13.33%	+330.82%	+814.57%	3.34B
BGI GENOMICS CO., LTD.	-0.99%	+0.80%	-8.74%	-15.35%	2.55B
FREENOME, INC.	-1.67%	-3.25%	+50.19%	-	1.74B
SEEGENE, INC.	-1.75%	-1.46%	+35.34%	+57.85%	1.15B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+0.26%	+2.55%	+170.32%	-23.50%	1.14B
CURIOX BIOSYSTEMS CO., LTD	+6.56%	+13.56%	-17.54%	+143.91%	636M
Average	+3.42%	+7.85%	+125.92%	+182.15%	2.37B
Weighted average by Cap.	+6.81%	+12.36%	+201.19%	+283.32%

	2023	2024
Net sales	8.43B 6.22M 5.48M 5.19M 4.71M 8.82M 596M 8.91M 62.26M 23.99M 305M 23.34M 22.83M 980M	1.25B 919K 811K 767K 696K 1.3M 88.17M 1.32M 9.2M 3.55M 45.02M 3.45M 3.38M 145M
Net income	-20.32B -14.98M -13.22M -12.51M -11.34M -21.27M -1.44B -21.48M -150M -57.83M -734M -56.25M -55.03M -2.36B	-52.34B -38.59M -34.06M -32.22M -29.22M -54.79M -3.7B -55.33M -387M -149M -1.89B -145M -142M -6.08B
Net Debt	7.2B 5.31M 4.69M 4.44M 4.02M 7.54M 510M 7.62M 53.21M 20.51M 260M 19.95M 19.51M 838M	7.03B 5.18M 4.57M 4.33M 3.93M 7.36M 497M 7.43M 51.92M 20.01M 254M 19.46M 19.04M 817M